FDA approves niraparib for first-line maintenance of advanced ovarian cancer
The Food and Drug Administration (FDA) approved niraparib for the maintenance treatment of adult patients…
Browsing: niraparib
Ovarian cancer drug niraparib maintains remission and extends time without symptoms
Findings from a recent clinical trial presented today at the Society of Gynecologic Oncology’s 50th…
ESMO 2016: Niraparib significantly improves outcome of ovarian cancer patients in landmark trial
The PARP inhibitor niraparib significantly improves the outcome of platinum-sensitive recurrent ovarian cancer, according to…